Novo Nordisk Drops Lawsuit, Yet Hims & Hers Faces Persistent Regulatory and Operational Headwinds

What happened

Novo Nordisk has dropped its patent lawsuit against Hims & Hers, which sought a permanent injunction through 2031 against the company's GLP-1 compounding activities. This news spurred a sharp rebound in HIMS shares, as investors had viewed the litigation as a major overhang on the stock. However, the DeepValue report highlights that Hims & Hers still confronts multiple federal investigations, including an SEC enforcement probe and a potential DOJ action stemming from an HHS referral. Additionally, FDA restrictions on compounded semaglutide and operational challenges from shifting to 503A fulfillment, with a disclosed $65 million Q1 revenue headwind, continue to pressure the business. While the lawsuit's removal eases one legal threat, the broader regulatory environment and execution risks remain significant obstacles to sustainable growth.

Implication

Investors should not overstate the positive impact of the lawsuit dismissal, as Hims & Hers remains exposed to SEC and DOJ investigations that could result in fines or business restrictions. The FDA's tightened posture on GLP-1 compounding directly threatens a core revenue driver, with personalized offerings including these drugs accounting for over 70% of U.S. sales. Operational shifts, such as the move to 503A fulfillment, are already causing revenue headwinds and may erode margins if not managed effectively. At a P/E of 27.8 and EV/EBITDA of 25.2, coupled with high net debt, the stock offers little margin of safety if guidance is missed due to these persistent issues. Therefore, a cautious approach is warranted, focusing on Q1 results and further legal developments before considering any investment re-evaluation.

Thesis delta

The investment thesis shifts slightly as the removal of Novo Nordisk's lawsuit reduces the probability of an immediate injunction, potentially tilting the risk-reward balance away from the worst-case Bear scenario. However, the core thesis remains largely intact, as significant regulatory risks from the FDA, SEC, and DOJ, along with operational headwinds, continue to skew the downside and challenge FY2026 guidance assumptions. This news does not materially alter the fundamental uncertainties around GLP-1 access or the company's ability to pivot without margin erosion.